Tag Archive for: Lonza

Lonza’s Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC

/in

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza’s commitment to helping customers deliver innovative new therapies to patients by offering a comprehensive service offering for differentiated ADCs BigHat’s artificial intelligence (AI)/machine learning (ML)-powered antibody design platform, Milliner™ was used to design a highly differentiated […]

Read more

Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering

/in

Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs) Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology Lonza and Synaffix will continue to expand their Center of Excellence for bioconjugate technology development, […]

Read more